Source: Benzinga

Kura: Kura Oncology to Report First Quarter 2025 Financial Results

SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the "Company") (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will report first quarter 2025 financial results after the close of U.S. financial markets on Thursday, May 1, 2025. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss the financial results and provide a corporate update.The live call may be accessed by dialing (800) 245-3047 for domestic callers and (203) 518-9765 for international callers and entering the conference ID: KURAQ1. A live webcast and archived replay of the event will be available here or online ...Full story available on Benzinga.com

Read full article »
Annual Revenue
$100-500M
Employees
100-250
Troy Wilson's photo - President & CEO of Kura

President & CEO

Troy Wilson

CEO Approval Rating

74/100

Read more